Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

Completed · Phase 4 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus (SLE)

In brief

This Phase 4 study is being performed to examine the effects of Acthar for the indicated use of treatment of SLE. This study will enroll patients with steroid-dependent, persistently active SLE with arthritic and/or cutaneous involvement. The study will involve two periods: an 8-week double-blind period, to provide placebo-controlled safety, efficacy, and pharmacodynamic data, and an optional open-label period, to examine the prolonged effects of Acthar maintenance.

Key facts

Study ID

NCT01753401

Run by

Mallinckrodt

People needed

38

Starts

2013-01-01

Expected to finish

2015-10-01

Last updated by the study team

2020-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥ 18 years of age at screening who are able to provide informed consent
• Diagnosis of SLE according to the American College of Rheumatology revised criteria (fulfilled ≥ 4 criteria)
• Active SLE with arthritic and/or cutaneous involvement as demonstrated by a SELENA-SLEDAI score ≥ 2 (clinical manifestation must include rash and/or arthritis)
• Moderate to severe rash and/or arthritis as demonstrated by BILAG score A or B in the mucocutaneous and/or musculoskeletal body systems
• Documented history of autoantibodies to at least one of the following: anti-dsDNA, anti-Smith, or anti-cardiolipin
• Documented history of positive antinuclear antibody (ANA)
• Currently on a stable dose of prednisone (7.5 to 30 mg/day of prednisone or equivalent within the 4 weeks prior to screening). The prednisone regimen must remain stable through the double-blind phase and until the stable Acthar regimen is attained in the open-label phase.

You may not qualify if…

• Patients with a recent history (≤ 2 months prior to screening) of starting prednisone (or equivalent) use
• Patients with active nephritis defined as serum creatinine > 2.5 mg/dL or protein creatinine ratio (PCR) > 1.5 g/g, or patients that required hemodialysis within 3 months prior to screening
• Active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis), requiring therapeutic intervention within 3 months prior to screening
• Type 1 or type 2 diabetes mellitus (history of gestational diabetes mellitus is not an exclusion), or patients currently taking hypoglycemic medication
• History of using certain medications prior to screening:
• oral prednisone (or equivalent) > 30 mg/day, any steroid injection, cyclosporine, or non-biologic investigational drug within 3 months prior to screening
• intravenous immunoglobulin (IVIg) or plasmapheresis within 4 months prior to screening
• cyclophosphamide within 6 months prior to screening; and/or
• B-cell targeted therapy, abatacept, or any biologic investigational agent within 12 months prior to screening
• Contraindication per Acthar Prescribing Information: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction
• For the purposes of this study, osteoporosis is defined as evidence of vertebral or long bone fracture or vertebral T-score > 2.0
• For the purposes of this study, history of peptic ulcer is defined as ≤ 6 months prior to screening
• For the purposes of this study, congestive heart failure is defined as New York Heart Association Functional Class III-IV

Where it is running

• Mallinckrodt Investigational Site — Jonesboro, Arkansas, United States
• Mallinckrodt Investigational Site — La Jolla, California, United States
• Mallinckrodt Investigational Site — La Palma, California, United States
• Mallinckrodt Investigational Site — Long Beach, California, United States
• Mallinckrodt Investigational Site — Upland, California, United States
• Mallinckrodt Investigational Site — Brandon, Florida, United States
• Mallinckrodt Investigational Site — Clearwater, Florida, United States
• Mallinckrodt Investigational Site — Miami Lakes, Florida, United States
• Mallinckrodt Investigational Site — Orlando, Florida, United States
• Mallinckrodt Investigational Site — Tampa, Florida, United States
• Mallinckrodt Investigational Site — Granger, Indiana, United States
• Mallinckrodt Investigational Site — Baton Rouge, Louisiana, United States
• Mallinckrodt Investigational Site — Lansing, Michigan, United States
• Mallinckrodt Investigational Site — Lansing, Michigan, United States
• Mallinckrodt Investigational Site — Brooklyn, New York, United States
• Mallinckrodt Investigational Site — Great Neck, New York, United States
• Mallinckrodt Investigational Site — New York, New York, United States
• Mallinckrodt Investigational Site — Charlotte, North Carolina, United States
• Mallinckrodt Investigational Site — Hershey, Pennsylvania, United States
• Mallinckrodt Investigational Site — Wyomissing, Pennsylvania, United States
• Mallinckrodt Investigational Site — Houston, Texas, United States
• Mallinckrodt Investigational Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.